CMAR_A_328737 7897..7908

Background Evidence has indicated that dysregulation of long noncoding RNAs (lncRNA) is a critical factor in the occurrence of many diseases, including cancer. The lncRNA AFAP1-AS1 has been shown to participate in oncogenesis, metastasis, or drug resistance in many types of cancer. However, the potential role of AFAP1-AS1 in oral squamous cell carcinoma (OSCC) has not been fully elucidated. Methods Bioinformatics analysis was performed to compare AFAP1-AS1 expression levels in OSCC cancer samples and in normal controls. The biological function of AFAP1-AS1 was studied through loss-of-function assays. To study the potential mechanisms, high-throughput sequencing was applied to OSCC cancer samples and a series of bioinformatics analyses were performed. The effects of AFAP1-AS1 on OSCC tumor growth was evaluated by in vivo xenograft tumor formation assays. Results Bioinformatics analyses indicated that AFAP1-AS1 was upregulated in OSCC. Overexpression of AFAP1-AS1 was positively correlated with lymph node metastasis, tumor stage, and pathological grade. Down-regulation of AFAP1-AS1 in OSCC led to decreased proliferation in vitro and, notably, inhibition of tumor growth in vivo. Further research indicated that AFAP1-AS1 regulated OSCC cell proliferation by targeting CCNA2. Conclusion AFAP1-AS1 promotes tumor proliferation and indicates a poor prognosis in OSCC, providing a potential therapeutic strategy.

[1]  Zhihong Li,et al.  Long non-coding RNA AFAP1-AS1 facilitates the growth and invasiveness of oral squamous cell carcinoma by regulating the miR-145/HOXA1 axis , 2020, Oncology Report.

[2]  Qian Wu,et al.  miR-27b Suppresses Tongue Squamous Cell Carcinoma Epithelial–Mesenchymal Transition by Targeting ITGA5 , 2020, OncoTargets and therapy.

[3]  Y. Ciribilli,et al.  MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis , 2020, International journal of molecular sciences.

[4]  H. Yao,et al.  Nanoparticles (NPs)‐Meditated LncRNA AFAP1‐AS1 Silencing to Block Wnt/β‐Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy , 2020, Advanced science.

[5]  Wei Zhang,et al.  Silencing lncRNA AFAP1-AS1 Inhibits the Progression of Esophageal Squamous Cell Carcinoma Cells via Regulating the miR-498/VEGFA Axis , 2020, Cancer management and research.

[6]  Xiao-na Zhang,et al.  Long noncoding RNA AFAP1-AS1 promotes osteosarcoma progression by regulating miR-497/IGF1R axis. , 2020, American journal of translational research.

[7]  Q. Sun,et al.  lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression , 2020, Scientific Reports.

[8]  F. Gao,et al.  Correction to: LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway , 2020, Journal of experimental & clinical cancer research : CR.

[9]  GuanNing Shang,et al.  Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis , 2020, BMC Cancer.

[10]  M. Guo,et al.  Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Metastasis via the miR-155-5p/FGF7 Axis and Predicts Poor Prognosis in Gastric Cancer , 2020, Disease markers.

[11]  Xihui Wang,et al.  AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway , 2019, Oncology letters.

[12]  Li Zhao,et al.  LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis , 2019, Journal of Hematology & Oncology.

[13]  F. Gao,et al.  LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[14]  Yingying Zhao,et al.  LncRNA GAS8-AS inhibits colorectal cancer (CRC) cell proliferation by downregulating lncRNA AFAP1-AS1. , 2019, Gene.

[15]  Yun Cui,et al.  LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc , 2019, Nature Communications.

[16]  P. Hershberger,et al.  Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. , 2019, Trends in cancer.

[17]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[18]  Ryan J Li,et al.  Contemporary Treatment of Locally Advanced Oral Cancer , 2019, Current Treatment Options in Oncology.

[19]  Jie Liu,et al.  Cross-talk among AFAP1-AS1, ACVR1 and microRNA-384 regulates the stemness of pancreatic cancer cells and tumorigenicity in nude mice , 2019, Journal of Experimental & Clinical Cancer Research.

[20]  Kai Yang,et al.  Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma , 2019, Cell Death & Disease.

[21]  A. van den Berg,et al.  Intricate crosstalk between MYC and non‐coding RNAs regulates hallmarks of cancer , 2018, Molecular oncology.

[22]  Y. Kong,et al.  AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer , 2018, Front. Pharmacol..

[23]  Yun Zhao,et al.  Long non-coding RNA AFAP1-AS1 plays an oncogenic role in promoting cell migration in non-small cell lung cancer , 2018, Cellular and Molecular Life Sciences.

[24]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[25]  Q. Lan,et al.  Long non-coding RNA AFAP1-AS1 accelerates invasion and predicts poor prognosis of glioma. , 2018, European review for medical and pharmacological sciences.

[26]  E. Zhang,et al.  Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non–small cell lung cancer cell proliferation by epigenetically repressing p21 expression , 2018, Molecular cancer.

[27]  Shuna Wang,et al.  LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma , 2018, Bioscience reports.

[28]  Ye Tian,et al.  Down-regulation of long non-coding RNA AFAP1-AS1 inhibits tumor growth, promotes apoptosis and decreases metastasis in thyroid cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  Yuchen Liu,et al.  AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers , 2018, Cell proliferation.

[30]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[31]  Y. Qiu,et al.  miR-145-5p Suppresses Tumor Cell Migration, Invasion and Epithelial to Mesenchymal Transition by Regulating the Sp1/NF-κB Signaling Pathway in Esophageal Squamous Cell Carcinoma , 2017, International journal of molecular sciences.

[32]  Yue Zhao,et al.  Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells , 2017, Cell Death Discovery.

[33]  Jun-qiang Guo,et al.  Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Apoptosis of Gastric Cancer Cells via PTEN/p-AKT Pathway , 2017, Digestive Diseases and Sciences.

[34]  Shouhua Wang,et al.  Overexpression of LncRNA AFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[35]  J. O’Sullivan,et al.  Oral cancer: Deregulated molecular events and their use as biomarkers. , 2016, Oral oncology.

[36]  F. Sun,et al.  Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[37]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[38]  M. Weng,et al.  Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/Rac2 signaling. , 2016, International journal of oncology.

[39]  A. Forastiere,et al.  Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. , 2016, Mayo Clinic proceedings.

[40]  Hongliang Zhu,et al.  Unveiling the hidden function of long non-coding RNA by identifying its major partner-protein , 2015, Cell & Bioscience.

[41]  Tao Xi,et al.  miR-31 promotes proliferation of colon cancer cells by targeting E2F2 , 2014, Biotechnology Letters.

[42]  J. Ji,et al.  CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance , 2014, PloS one.

[43]  S. Meltzer,et al.  Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. , 2013, Gastroenterology.

[44]  David G. Knowles,et al.  The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression , 2012, Genome research.

[45]  J. Rinn,et al.  Modular regulatory principles of large non-coding RNAs , 2012, Nature.

[46]  A. García-García,et al.  What real influence does the proto-oncogene c-myc have in OSCC behavior? , 2011, Oral oncology.

[47]  M. Malumbres,et al.  E2F2 represses cell cycle regulators to maintain quiescence , 2008, Cell cycle.

[48]  S. Robson,et al.  c-Myc and downstream targets in the pathogenesis and treatment of cancer. , 2006, Recent patents on anti-cancer drug discovery.

[49]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Blanchard.  Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues. , 2000, Biochemical pharmacology.